Recently, President Trump clarified his stance on marijuana, emphasizing its complex nature but also acknowledging the significant benefits, particularly in medical contexts. It’s a complicated issue, no doubt, but one that deserves attention.
He’s not the only one with this perspective. Former Congressman Bob Barr (R-Ga.) previously argued that the classification of marijuana hampered research and medical practices, pointing out that its current scheduling is outdated. He emphasized the need to reduce bureaucratic hurdles, which could foster job creation and pave the way for new medical advancements.
A few weeks ago, an alliance representing over 40 patient organizations, which includes my own, sent a letter to Congress urging them to safeguard medical marijuana programs. In it, they described these programs as essential lifelines for millions of Americans.
This letter called for comprehensive, lasting federal legislation that would harmonize federal and state cannabis policies, integrating medical marijuana into standard healthcare frameworks. The aim is to secure ongoing support for needed reforms.
Should the Drug Enforcement Administration (DEA) heed the recommendations from the Department of Health and Human Services and classify cannabis as Schedule III, it could simplify and reduce the costs related to research on its medical applications.
Medical associations have stated that adhering to Schedule III security requirements is less cumbersome than those for Schedule I substances, thereby enhancing the ability for research to proceed.
Such a change could also lessen stigma around cannabis use, possibly leading to broader acceptance among healthcare professionals and policymakers.
However, simply reclassifying cannabis won’t resolve all the systemic obstacles faced by patients and businesses. Even with Schedule III, cannabis still wouldn’t be deemed “legal” under federal law, nor would it necessarily improve state programs or restore rights to patients.
At present, state medical cannabis programs, while protected from federal interference, depend on Congress for yearly renewal of these protections.
Contrary to statements made by opponents of cannabis and certain advocacy groups, IRS regulations probably won’t change, thus denying cannabis businesses the ability to deduct standard business expenses under federal laws, even if Schedule III is established.
This regulatory landscape remains perplexing, especially given governmental research that shows medical marijuana can be both safe and effective. The FDA has indicated that there are no significant safety concerns related to cannabis use for approved medical benefits.
The advantages of medical cannabis are tangible and are already making a difference in many lives.
For example, older adults represent one of the largest segments of cannabis users. Research shows that one in five Americans aged 50-80 have turned to cannabis for pain relief or sleep issues. National surveys have also indicated that many veterans use cannabis to manage chronic pain, PTSD, and other health issues.
Moreover, studies reveal that a notable portion of patients dealing with chronic pain are using cannabis to enhance their quality of life and potentially reduce reliance on opioids. In 2021, the CDC reported that over 51 million adults in the U.S. live with chronic pain.
This situation is further complicated because chronic conditions contribute significantly to the nation’s annual medical expenses, which run into the trillions. Many patients find existing treatments inadequate, while cannabis often provides multifaceted relief with fewer risks, even as it remains classified as a controlled substance.
Additionally, a significant percentage of cancer patients have reported using cannabis for various symptoms, encompassing sleep and mood management as well as pain relief.
During his presidency, Trump prioritized addressing the opioid crisis. Research indicates that increasing access to cannabis might play a crucial role in resolving this public health issue. A recent op-ed highlighted data suggesting that regions with cannabis dispensaries have seen a marked decrease in opioid-related deaths shortly after the establishment of these services.
This is an important public health outcome that policymakers should not overlook.
Furthermore, without federal reform, the U.S. risks falling behind in the global medical cannabis market, where nearly 60 countries have already set up national programs offering standardized cannabis products to their patients.
American businesses, constrained by a patchwork of state laws and barred from interstate trade, struggle to compete internationally. This seems at odds with the administration’s framework focused on American innovation and manufacturing.
What can the president do? Well, he has several options at his disposal:
- Finalize the rescheduling process. He could instruct the DEA to adopt the Schedule III recommendations from HHS to expedite rulemaking.
- Avoid budget pitfalls. The president could encourage Congress to remove any funding threats that could jeopardize healthcare programs related to medical cannabis.
- Establish an office for medical cannabis oversight. Collaborating with HHS to form a regulatory body for cannabis could foster better management of medical cannabis issues.
- Push for formal legislation. He could work with Congress to establish bipartisan laws that would govern medical cannabis effectively, benefiting patients, science, and domestic manufacturers.
Indeed, medical cannabis policies are intricate. Yet, this complexity presents an opportunity for substantial progress, aligning with the proactive spirit that has characterized Trump’s approach. With millions of patients and numerous jobs at stake, as well as America’s position in an expanding global industry, there’s much to gain.
It’s time to acknowledge cannabis’s accepted medical use, protect patients, and foster a federal framework that encourages innovation in healthcare and supports medical professionals. This is a tangled yet important endeavor.
